Lataa...
Hearing Loss and Teprotumumab
Thyroid eye disease (TED) is an unpredictable autoimmune inflammatory disease which can be sight-threatening, debilitating, and disfiguring. Teprotumumab (IV infusion every 3 weeks x 8 doses) was recently approved as the first and only FDA-approved drug for TED in 2020. Phase 2 and 3 studies showed...
Tallennettuna:
| Julkaisussa: | J Endocr Soc |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8089925/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1713 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|